PPG volunteers to beautify 25 schools with New Paint for a New Start initiative
6.6.2024 16:00:00 EEST | Business Wire | Press release
PPG (NYSE:PPG) today announced that its New Paint for a New Start initiative, part of the company’s COLORFUL COMMUNITIES® program, will complete more than 25 colorful and transformative school and educational space makeovers worldwide by the end of August 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606627586/en/
PPG volunteers paint a school in Nickerie, Suriname, as part of the New Paint for a New Start initiative, part of the company’s COLORFUL COMMUNITIES® program. (Photo: Business Wire)
In the third year of New Paint for a New Start, PPG employees will build on the positive impact that new colors and improved learning environments have on students and teachers by volunteering their time, partnering with PPG customers and activating elements of environmental sustainability. Using PPG paint products and color expertise, each project aims to create engaging spaces for students to learn and grow.
“The impacts of a quality education hold significant value and can change the trajectory of a student’s life. Our employee volunteers recognize this as they step into schools and educational spaces to paint classrooms and brighten places where students can thrive,” said Malesia Dunn, executive director, PPG Foundation and corporate global social responsibility. “Each New Paint for a New Start project aims to create joyful spaces where students feel supported and enable possibilities and progress in the lives of young people.”
Most of the transformation projects will use a global color palette, including PPG’s 2024 Color of the Year, Limitless. PPG experts selected colors that pair well with various learning objectives and work to elevate and enhance the physical classroom environments.
“Color is a powerful communicator and can play a meaningful role in engaging students and connecting with learning objectives within a classroom,” said Steve Pocock, PPG vice president EMEA West and Central, Architectural Coatings, and 2024 New Paint for a New Start executive champion. “From Milan, Italy to Zhangjiagang, China and many places in between, PPG volunteers are expanding the transformative impacts of beautifying schools worldwide. In 2024, we’re excited to be joined by several PPG customers to deepen the reach of the initiative.”
In addition to painting spaces, PPG and the PPG Foundation are also supplying several New Paint for a New Start schools with funding for science, technology, engineering and mathematics (STEM) education supplies.
In 2022 and 2023, more than 60 schools and educational spaces were transformed as part of New Paint for a New Start, improving classrooms and learning spaces for more than 35,000 students and educators. Learn more here.
PPG’s global community engagement efforts and the PPG Foundation aim to bring color and brightness to PPG communities around the world. We invested more than $17.5 million in 2023, supporting hundreds of organizations across nearly 40 countries. By investing in educational opportunities, we help grow tomorrow’s STEM innovators and skilled workforce in fields related to coatings and manufacturing. Plus, we empower PPG employees to multiply their impact for causes that are important to them by supporting their volunteer efforts and charitable giving. Learn more here.
PPG: WE PROTECT AND BEAUTIFY THE WORLD®
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for more than 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $18.2 billion in 2023. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.
Colorful Communities, the PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc.
CATEGORY Community Affairs
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606627586/en/
Contact information
PPG Media Contact:
Mark Silvey
Corporate Communications
silvey@ppg.com
www.ppgcommunities.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom